REDWOOD CITY, Calif. and FARGO, N.D., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with...
Aldevron, a global manufacturer of DNA, RNA and proteins used in cell and gene therapies and vaccine development, is expanding its mRNA production capabilities to include lipid nanoparticle?(LNP) encapsulation and aseptic fill-finish capabilities enabling mRNA cGMP manufacturing services from master cell bank?through to drug product. The expansion is expected to be fully online in the second half of 2023.
Aldevron, a subsidiary of Danaher, unveiled plans to expand its mRNA manufacturing operations to include lipid nanoparticle (LNP) encapsulation and aseptic fill-finish capabilities.
En route to entering the clinic with its first AAV-based gene therapy for a rare neuromuscular disease, AavantiBio has let go of 30 employees, Endpoints News has learned.
Fargo-based DNA and mRNA producer Aldevron has signed an agreement with life sciences company Inscripta to manufacture and commercialize the Eureca-V Nuclease, a wild-type MAD7 CRISPR Type-V nuclease.
Aldevron, a research to GMP biomanufacturer of plasmid DNA, mRNA, and proteins, and Ginkgo Bioworks, Inc., announced a manufacturing breakthrough leveraging their strategic partnership.
After partnering with biomanufacturing expert Aldevron earlier this year, Ginkgo Bioworks has notched a win in the red-hot mRNA manufacturing field.
After partnering with biomanufacturing expert Aldevron earlier this year, Ginkgo Bioworks has notched a win in the red-hot mRNA manufacturing field.
NEW YORK, BASEL, Switzerland and Fargo, N.D., June 16, 2021 /PRNewswire/ -- Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Aldevron, the leading provider of high-quality plasmid DNA, mRNA and recombinant proteins necessary for vaccines, gene and cell therapy, gene editing and diagnostic applications, announced today that Aldevron will support the development of ARU-1801, Aruvant's one-time investigational gene therapy for sickle cell disease (SCD), and ARU-2801, a one-time investigational gene therapy for hypophosphatasia (HPP). Aldevron will provide good manufacturing practice (GMP)-grade plasmid for Aruvant's upcoming ARU-1801 pivotal trial.